Abstract
Restless legs syndrome is an underdiagnosed sensori-motor disorder and psychotropic drugs are one of the main secondary causes of the illness. The most common psychotropic agents that cause restless legs syndrome are antidepressants; however, antipsychotics have also been reported to induce restless legs syndrome. The prevalence, vulnerability factors and the underlying mechanism of antipsychotic-induced restless legs syndrome are unclear. A possible explanation is that dopaminergic blockade is the main precipitator of the syndrome. Quetiapine-induced restless legs syndrome is another point of interest because of its low binding to D2 receptors. We herein report the case of a restless legs syndrome that emerged after a single low dose quetiapine administration.
Keywords: Restless legs syndrome, clozapine, psychotropic drugs, quetiapine, risperidone.
Current Drug Safety
Title:Restless Legs Syndrome After Single Low Dose Quetiapine Administration
Volume: 11 Issue: 2
Author(s): Ahmet Z. Soyata, Fahri Celebi and Lutfi I. Yargc
Affiliation:
Keywords: Restless legs syndrome, clozapine, psychotropic drugs, quetiapine, risperidone.
Abstract: Restless legs syndrome is an underdiagnosed sensori-motor disorder and psychotropic drugs are one of the main secondary causes of the illness. The most common psychotropic agents that cause restless legs syndrome are antidepressants; however, antipsychotics have also been reported to induce restless legs syndrome. The prevalence, vulnerability factors and the underlying mechanism of antipsychotic-induced restless legs syndrome are unclear. A possible explanation is that dopaminergic blockade is the main precipitator of the syndrome. Quetiapine-induced restless legs syndrome is another point of interest because of its low binding to D2 receptors. We herein report the case of a restless legs syndrome that emerged after a single low dose quetiapine administration.
Export Options
About this article
Cite this article as:
Z. Soyata Ahmet, Celebi Fahri and I. Yargc Lutfi, Restless Legs Syndrome After Single Low Dose Quetiapine Administration, Current Drug Safety 2016; 11 (2) . https://dx.doi.org/10.2174/1574886311207040298
DOI https://dx.doi.org/10.2174/1574886311207040298 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
In Vivo Beta-Cell Imaging with VMAT 2 Ligands - Current State-of-the-Art and Future Perspectives
Current Pharmaceutical Design Synthesis and Evaluation of 2-benzylidene-1-tetralone Derivatives for Monoamine Oxidase Inhibitory Activity
Central Nervous System Agents in Medicinal Chemistry Effects of Melatonin on Peripheral Nerve Regeneration
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Medical Treatment of Malignancy-Associated Hypercalcemia
Current Medicinal Chemistry Editorial [Hot Topic: Cannabinoid Receptors Ligands (Guest Editor: Gabriele Murineddu)]
Recent Patents on CNS Drug Discovery (Discontinued) Alternative Aβ Immunotherapy Approaches for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Discovery of Selective Probes and Antagonists for G Protein-Coupled Receptors FPR/FPRL1 and GPR30
Current Topics in Medicinal Chemistry Effects of SORL1 Gene on Alzheimer's Disease. Focus on Gender, Neuropsychiatric Symptoms and Pro-Inflammatory Cytokines
Current Alzheimer Research Central Nervous System Abnormalities in Fibromyalgia and Chronic Fatigue Syndrome: New Concepts in Treatment
Current Pharmaceutical Design Brain Connectivity Studies in Schizophrenia: Unravelling the Effects of Antipsychotics
Current Neuropharmacology Alternatively Spliced Genes as Biomarkers for Schizophrenia, Bipolar Disorder and Psychosis: A Blood-Based Spliceome-Profiling Exploratory Study (Supplementry Table)
Current Pharmacogenomics and Personalized Medicine Lysosomal Molecules are Up-Regulated in the Articular Cartilage Explants Subjected to Oxidative Stress and in the Cartilage from an Osteoarthritis-Induced Rat Model
Recent Patents on Biomarkers A2A Adenosine Receptor and its Modulators: Overview on a Druggable GPCR and on Structure-Activity Relationship Analysis and Binding Requirements of Agonists and Antagonists
Current Pharmaceutical Design Tianeptine: An Antidepressant with Memory-Protective Properties
Current Neuropharmacology Glutamate-Mediated Signaling and Autism Spectrum Disorders: Emerging Treatment Targets
Current Pharmaceutical Design Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder
Current Drug Metabolism Alkaloids and Flavonoids as α1-Adrenergic Receptor Antagonists
Current Medicinal Chemistry Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview
Current Alzheimer Research Salvinorin A and Related Compounds as Therapeutic Drugs for Psychostimulant-Related Disorders
Current Drug Abuse Reviews Determinants of Anti-Cancer Effect of Mitochondrial Electron Transport Chain Inhibitors: Bioenergetic Profile and Metabolic Flexibility of Cancer Cells
Current Pharmaceutical Design